2023-06-19
At the Open Day at our state-of-the art cell and gene therapy facility, we welcomed close to 100 guests: fund managers, analysts, individual investors, media, representatives of government agencies, the EU commission and medical centres.
Thank you for your participation. We were delighted to host such a distinguished assembly.
See you next time!
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
2024-06-25
PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk
2024-06-24
Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes
2024-06-13
PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment
